DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/04/3211-1304-1310$20.00
DMD 32:1304-1310, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silva, M. F. B.
Right arrow Articles by Wanders, R. J. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Silva, M. F. B.
Right arrow Articles by Wanders, R. J. A.

VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA

Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida, and Ronald J. A. Wanders

Department of Clinical Chemistry and Pediatrics, University of Amsterdam, Amsterdam, The Netherlands (M.F.B.S., L.I., M.D., R.J.A.W.); Centro de Patogénese Molecular, Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal (M.F.B.S., I.T.d.A.); University Children's Hospital, Utrecht, The Netherlands (P.A.); and Department of Clinical Chemistry, Free University Hospital, Amsterdam, The Netherlands (C.J.)

The mitochondrial metabolism of valproic acid (VPA) was investigated in vitro to elucidate its ß-oxidation pathway since the characterization of VPA intermediates in the acyl-CoA thioester form, and not just in their free acid form, has not been fully achieved. Intact rat liver mitochondria were incubated with [4,5-3H2]VPA and [2-3H]VPA. The respective intermediates, valproyl-CoA, {Delta}2(E)-valproyl-CoA, 3-hydroxyvalproyl-CoA, and 3-oxovalproyl-CoA were analyzed by reverse phase high performance liquid chromatography (HPLC) with radioisotope and UV detection. An unknown metabolite, originating from both labeled substrates, was detected. It was identified as valproyl-dephosphoCoA (valproyl-dephCoA) by fast atom bombardment mass spectrometry (FAB-MS) analysis of the corresponding HPLC peak fraction. The FAB-MS spectrum of the authentic chemically synthesized valproyl-dephCoA proved to be consistent with that of the unknown compound. Valproyl-dephCoA is produced from valproyl-CoA in mitochondria, probably via a phosphatase-catalyzed reaction. This conversion was shown to be more dependent on the energy state involving [AXP] ([AXP] = [ATP] + [ADP] + [AMP]) and [phosphate] concentrations rather than the strict mitochondrial [ATP]/[ADP] ratio. The results indicate that higher concentrations of AXP and phosphate inhibit the dephosphorylation of valproyl-CoA. A complete understanding of the toxic significance of valproyl-dephCoA formation in vivo as a potential inhibitor of fatty acid ß-oxidation is important to clarify the pathogenesis of VPA-associated hepatotoxicity.

Address correspondence to: Dr. Margarida F. B. Silva, Centro de Patogénese Molecular - Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal. E-mail: mbsilva{at}ff.ul.pt






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.